



Aalborg Universitet

AALBORG UNIVERSITY
DENMARK

Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry

Redder, Louise; Klausen, Tobias W; Vangsted, Annette Juul; Gregersen, Henrik; Andersen, Niels Frost; Pedersen, Robert S; Szabo, Agoston G; Frederiksen, Mikael; Frølund, Ulf C; Helleberg, Carsten; Nielsen, Lene Kongsgaard; Pedersen, Per T; Salomo, Morten; Gimsing, Peter; Frederiksen, Henrik; Abildgaard, Niels

Published in:
British Journal of Haematology

DOI (link to publication from Publisher):
[10.1111/bjh.16806](https://doi.org/10.1111/bjh.16806)

Publication date:
2021

Document Version
Accepted author manuscript, peer reviewed version

[Link to publication from Aalborg University](#)

Citation for published version (APA):
Redder, L., Klausen, T. W., Vangsted, A. J., Gregersen, H., Andersen, N. F., Pedersen, R. S., Szabo, A. G., Frederiksen, M., Frølund, U. C., Helleberg, C., Nielsen, L. K., Pedersen, P. T., Salomo, M., Gimsing, P., Frederiksen, H., & Abildgaard, N. (2021). Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. *British Journal of Haematology*, 193(1), 119-124. Advance online publication. <https://doi.org/10.1111/bjh.16806>

1

2 DR. LOUISE REDDER (Orcid ID : 0000-0003-3965-2025)

3 DR. ANNETTE JUUL VANGSTED (Orcid ID : 0000-0002-2131-731X)

4 DR. LENE KONGSGAARD NIELSEN (Orcid ID : 0000-0003-2083-3870)

5

6

7 Article type : Short Reports

8

9

10 Corresponding author mail id: louise.redder3@rsyd.dk

11

12 British Journal of Haematology

Short report

13

14 **Validation of the UK Myeloma Research Alliance Risk Profile, a**
15 **new Clinical Prediction Model for Outcome in Patients with**
16 **Newly Diagnosed Multiple Myeloma not Eligible for Autologous**
17 **Stem-Cell Transplantation; A Population-Based Study from the**
18 **Danish National Multiple Myeloma Registry**

19 **Louise Redder, MD¹**, Tobias Wirenfeldt Klausen, M.S.², Annette Juul Vangsted, MD, PhD³, Henrik
20 Gregersen, MD, PhD⁴, Niels Frost Andersen, MD, PhD⁵, Robert Schou Pedersen, MD, PhD⁶, Agoston
21 Gyula Szabo MD⁷, Mikael Frederiksen, MD⁸, Ulf Christian Frølund, MD⁹, Carsten Helleberg, MD²,
22 Lene Kongsgaard Nielsen, MD, PhD^{1,10}, Per Trøllund Pedersen, MD¹¹, Morten Salomo, MD, PhD³,

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/BJH.16806](https://doi.org/10.1111/BJH.16806)

This article is protected by copyright. All rights reserved

23 Peter Gimsing, MD, DMSc³, Henrik Frederiksen, MD, Professor^{1,12,13} and Niels Abildgaard, MD,
24 Professor^{1,12,13}

25 ¹Department of Haematology, Odense University Hospital, Odense, Denmark; ²Department of Haematology, Herlev
26 Hospital, Herlev, Denmark; ³Department Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen,
27 Denmark; ⁴Department of Haematology, Aalborg University Hospital, Aalborg, Denmark; ⁵Department of
28 Haematology, Aarhus University Hospital, Aarhus, Denmark; ⁶Department of Haematology, Holstebro Hospital,
29 Denmark; ⁷Department of Haematology, Vejle Hospital, Vejle, Denmark; ⁸Department of Haematology, Hospital of
30 Southern Jutland, Aabenraa, Denmark; ⁹Department of Haematology, Zealand University Hospital, Roskilde, Denmark;
31 ¹⁰Department of Internal Medicine and Cardiology, Regional Hospital Viborg, Denmark; ¹¹Department of Haematology,
32 South-Western Hospital, Esbjerg, Denmark; ¹²Academy of Geriatric Cancer Research (AgeCare), Odense University
33 Hospital, Odense, Denmark; ¹³Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

34

35 Introduction

36 The heterogeneity of patients with multiple myeloma (MM) is significant based on both the biology of the
37 malignant plasma cells and age and comorbidity of the patients, causing a wide range in survival from few
38 months to more than 10 years(Rajkumar, 2018). This has caused a need for prognostic models. The
39 International Staging System (ISS) was introduced in 2005(Greipp *et al*, 2005) and later improved by
40 inclusion of high-risk cytogenetic aberrations and lactate dehydrogenase (LDH) in the revised ISS (R-
41 ISS)(Palumbo *et al*, 2015a). A number of other scoring systems have been introduced that include patient
42 related factors, e.g. the IMWG frailty score (Palumbo *et al*, 2015b) the revised myeloma comorbidity index
43 (R-MCI)(Engelhardt *et al*, 2017), Haematopoietic Cell Transplant Comorbidity Index (HCT-CI)(Saad *et al*,
44 2014), Myeloma prognostic index(MPI) (Kim *et al*, 2017) and Charlson Comorbidity Index (CCI)(Bila *et al*,
45 2015). All of these have been tested in patients with MM, but not implemented in the daily clinic. Some of
46 the scores are rather time consuming to use, others have not achieved international credit and recognition,
47 which might be some of the reasons why consensus is still lacking in the field.

48 Latest, the UK Myeloma Research Alliance introduced a new clinical prediction model for outcome in
49 patients with newly diagnosed MM, ineligible for autologous haematopoietic stem-cell transplantation
50 (ASCT)(Cook *et al*, 2019). The score or Myeloma Risk Profile (MRP) includes WHO performance status (PS),
51 ISS stage, age and C-reactive protein (CRP) as prognostic variables. The score is calculated by the formula:
52 $\text{Score} = (\text{PS} - 2) * 0.199 + (\text{age} - 74.4) * 0.0165 + (\text{ISS} - 2) * 0.212 + (\log(\text{CRP} + 1) - 2.08) * 0.0315$, where PS
53 and ISS are defined as numbers between 0-4 and 1-3, respectively, and CRP is in mg/L. By this calculation,
54 patients with MM are stratified into one of the following three risk groups: low risk: score < -0.256, medium
55 risk: $-0.256 \leq \text{score} \leq -0.0283$ and high risk: score > -0.0283.

1 The MRP score was generated based on two prospective clinical trial cohorts; the NRCI-XI study(Jackson
2 *et al*, 2019) as training set or internal validation, and the MRC-IX study(Morgan *et al*, 2011) as test set or
3 external validation. Both trials investigated conventional oral alkylating agents, cyclophosphamide or
4 melphalan, in combination with thalidomide, lenalidomide, and/or bortezomib; thus including drugs
5 typically used in treatment of elderly patients with MM. Establishment of the model included 1,852
6 patients in the training set and 520 patients in the test set. All patients were recruited as part of clinical
7 trials and therefore met defined inclusion and exclusion criteria.

8 Since only 36.6 % of newly diagnosed patients with MM above 65 years in the general population meet
9 the inclusion criteria in clinical trials(Klausen *et al*, 2019), we found it relevant to validate the MRP score in
10 a population-based setting.

11 12 **Methods**

13 We performed a study of the entire cohort of newly diagnosed transplant ineligible patients with MM
14 above 65 years in the Danish National Multiple Myeloma Registry (DMMR). The DMMR includes all Danish
15 patients with MM diagnosed since the first of January 2005 and provides validated information about
16 baseline characteristics and first and second lines of therapy(Gimsing *et al*, 2016). Transplant ineligibility
17 was in the study period defined consistently according to the National MM guideline and registered in the
18 DMMR at diagnosis. Transplant eligibility in a patient above 65 years would as minimum request absence of
19 significant heart, lung and liver dysfunction and a good performance status.

20 At the 31th of December 2014, 2,926 patients with treatment demanding MM were registered, of whom
21 1,803 patients were above 65 years and found to be ineligible for ASCT, and constituted the patient
22 population for this study.

23 Of the study population, 426 patients had one or more missing values for calculation of the MRP score,
24 most often this was caused by missing ISS. Thus, 1,377 patients were evaluable with a median follow-up of
25 64.7 months (Table 1). Patients were treated according to standard of care in Denmark during the 10 year
26 registration period, which included an upfront conventional alkylating agent, most frequently melphalan in
27 37.7%, thalidomide-based in 25.6%, bortezomib-based in 26.1%, and lenalidomide based in 2.7% of cases,
28 while 7.9% received only palliative, mostly steroid-based therapy.

29 30 **Results**

31 When calculating the MRP score we found 28.5% to be low-risk, 25.1% medium-risk and 46.4% high-risk.
32 Compared to the UK dataset we found a higher proportion of high-risk patients. As shown in Figure 1, the
33 Kaplan-Meier curves separate into three risk groups, with a highly significant hazard ratio of 2.91 (95% CI:

1 2.49-3.40) in the high-risk group and 1.53 (95% CI: 1.27-1.83) in the medium risk group for prediction of risk
2 of death compared to the low-risk group. For the low-risk group we observed a median overall survival of
3 55.0 months in contrast to a median survival of only 13.9 months in the high-risk group and 35.9 month in
4 the medium-risk group (Table S1). The Kaplan-Meier curves for progression free survival (PFS) also showed
5 a significant spread with a hazard ratio of 2.06 (95% CI: 1.79-2.37) for prediction of risk of progression in
6 the high-risk group and 1.39 (95% CI: 1.17-1.63) in the medium risk group (Figure 1).

7 Treatment patterns have changed during the study period. To test the performance of the risk model over
8 time, we compared patients diagnosed from 2005-2009 with those diagnosed from 2010-2015. We
9 observed no significant difference in the performance of the model during the two periods (supplementary
10 Table S2). In test for interaction between year of diagnosis and MRP the p value was 0.5.

11 We looked further into the association between the MRP and other clinical and para-clinical data of
12 established prognostic or clinical importance, e.g. LDH, haemoglobin, creatinine, bone disease and
13 response to first-line of therapy(Rajkumar, 2018). As expected the high-risk group had significantly higher
14 creatinine, lower haemoglobin, marginally more advanced bone disease and higher LDH levels compared to
15 the low-risk and medium-risk groups (Table 1). However, in absolute figures the differences between these
16 variables in the three risk groups were not particularly evident. The outcome and responses to first line of
17 therapy were significantly different in the three groups. The proportions of early death and primary
18 refractory disease were highest in the high-risk group. Also, the median duration of first line therapy was
19 shorter in the high-risk group. Patients with high-risk scores had a significantly shorter median time on anti-
20 myeloma treatment, 132 days, than observed in the medium and low-risk groups; 191 and 216 days,
21 respectively ($P < 0.0001$). Achieved Very Good Partial Response (VGPR) or better was seen more frequently
22 in the low-risk group (Table 1).

23 In 426 patients (23.6%) one or more parameters for calculation of the MRP risk profile were lacking in our
24 material. The characteristics of patients with incomplete data are compared to the included patients in
25 Table S2. Patient age in the two subgroups was the same, but patients in the incomplete data group who
26 were diagnosed closer to start of the DMMR, received fewer novel drugs, had higher CRP values, and
27 shorter survival. The most common reason for missing data was lack of beta-2-microglobuline
28 measurement.

30 Discussion

31 The results align with the expectations to a prognostic risk profile and confirm that the MRP score divides
32 newly diagnosed elderly patients with MM who are ineligible for ASCT into truly different risk groups.

1 We would like to highlight the crucial importance of validating prognostic models in the general
2 population as we did in this study, particularly if the models are sought to be implemented in the daily clinic
3 and not only for risk group stratification in clinical trials. The MRP score does not include information on
4 comorbidity or patient frailty, besides PS as a potential surrogate, nor does it include functional testing,
5 such as geriatric assessments (Engelhardt *et al*, 2017)(Palumbo *et al* 2015). While inclusion of these factors
6 could improve the prognostic and predictive information of the score, it would make the scoring process
7 more burdensome and less feasible in the daily clinic. Improvement of the prognostic information could
8 though be expected by inclusion of high risk FISH aberrations as seen in the revised-ISS(Palumbo *et al*,
9 2015b).

10 An important aspect of a prognostic score is its ability to predict the feasibility of planned treatment. In
11 our population more early deaths, shorter PFS and lower treatment responses were observed in the MRP
12 high-risk group, and moreover, we observed that time on treatment was associated with the MRP score.
13 Thus, a MRP high-risk score identifies patients who are particularly challenged by early drop-out of
14 treatment. However, the reason for treatment discontinuation cannot be identified by our data, e.g.
15 whether it is caused by toxicity, lack of response, patient or physician decision. Prospective trials testing
16 different treatments and supportive care strategies in MRP high-risk patients should be performed.

17 Partly caused by the population-based nature of our dataset, complete data were not available in all
18 newly diagnosed patients. However, the population with missing data was comparable to the study
19 population in most parameters (Table S2) except that they were diagnosed earlier, had significantly higher
20 CRP and shorter survival. In most cases the missing data were due to lack of beta-2-microglobuline.
21 Combined with the observation of higher CRP values the most likely explanation for missing beta-2-
22 microglobuline and poorer prognosis in these patients is probably that they presented with infection and
23 were admitted to hospital in the late hours where focus on myeloma diagnostic work-up was low.
24 Moreover, because the patients were diagnosed in the earlier years of the registry, they seem to have
25 received less effective treatment and therefore had shorter survival. In the early years of the registry there
26 may also have been less focus on beta-2-microglobuline measurement and thereby ISS staging. However
27 when testing the performance of the MRP score over time we found no difference when comparing
28 patients diagnosed from 2005-2009 with patients from 2010-2015.

30 **Conclusion**

31 Our real world population-based data confirm that the MRP score is a robust and valuable risk assessment
32 tool for newly diagnosed patients with MM older than 65 years and ineligible for ASCT. An important
33 advantage of the MRP score is that it is calculated from easily accessible parameters that are part of the

1 routine diagnostic work-up of myeloma patients. Prospective trials testing different treatments and
2 supportive care strategies based on the Myeloma Risk Profile are warranted.

3

4

5 **Acknowledgements**

6 The work was supported by the Danish Cancer Society and the Academy of Geriatric Cancer Research
7 (AgeCare), Odense University Hospital, Denmark.

8 Author contributions LR, TWK, LKN, HF and NA conceived and designed the work, interpreted the results,
9 drafted the manuscript and approved the final version. AJV, HG, NFA, RSP, AGS, MF, UCF, CH, PTP, MS and
10 PG interpreted the results, revised the manuscript and approved the final version.

11 **Compliance with ethical standards**

12 The project has been approved by the Danish health authorities.

13

14 **Conflicts of interest**

15 The authors declare that they have no conflicts of interest.

16

References

Author Manuscript


Table 1. Patient demographics and clinical characteristics of 1,377 patients with newly diagnosed multiple myeloma according to Myeloma Risk Profile (MRP) risk groups

	Low-risk	Intermediate-risk	High-risk	P
Numbers of patients (%)	393 (28.5%)	345 (25.1%)	639 (46.4%)	
Variables included in MRP index				
Age, years (IQR)	72 (69-77)	75 (71-80)	78 (74-84)	
WHO Performance status				
0	196 (49.9%)	78 (22.6%)	8 (1.3%)	
1	183 (46.6%)	220 (63.8%)	182 (28.5%)	
2	14 (3.6%)	42 (12.2%)	233 (36.5%)	
3	0 (0%)	5 (1.4%)	140 (21.9%)	
4	0 (0%)	0 (0%)	76 (11.9%)	
C-reactive protein, mg/L (IQR)	4 (2-10)	5 (2-14)	12 (5-34)	
International Staging System				
I	259 (65.9%)	27 (7.8%)	21 (3.1%)	
II	121 (30.8%)	193 (55.9%)	182 (28.5%)	
III	13 (3.3%)	125 (36.2%)	437 (68.4%)	
Beta2-microglobuline, mg/L (IQR)	2.8 (2.2-3.6)	4.7 (3.8-6.7)	6.9 (4.9-11.8)	
Albumin, g/L (IQR)	39 (36-42)	34 (31-39)	32 (27-37)	
Other variables				
Gender				
Female	188 (47.8%)	154 (44.6%)	297 (46.5%)	0.74**

Male	205 (52.2%)	191 (55.3%)	342 (53.5%)	
Lactate dehydrogenase, U/L (IQR)	171 (146-205)	172 (145-220)	189 (148-243)	0.0001
Hemoglobin, mmol/L (IQR)	7.1 (6.5-8.0)	6.4 (5.7-7.0)	6.1 (5.6-6.7)	<0.0001
Creatinine, µmol/L (IQR)	80 (66-95)	98 (77-133)	117 (82-228)	<0.0001
Bone disease				0.027
None	65 (16.4%)	55 (16.1%)	95 (15.1%)	
Osteoporosis only	47 (12.0%)	48 (14.0%)	90 (14.3%)	
Few osteolytic lesions	113 (28.9%)	87 (25.4%)	124 (19.7%)	
Multiple osteolytic lesions	167 (42.7%)	152 (44.4%)	319 (50.8%)	
Treatment				
First line Treatment				
Alkylator based*	127 (35.2%)	111 (34.8%)	247 (40.7%)	<0.0001
Thalidomide based	106 (29.4%)	94 (29.5%)	129 (21.3%)	
Lenalidomide based	19 (5.3%)	8 (2.5%)	8 (1.3%)	
Bortezomib based	90 (24.9%)	91 (28.5%)	155 (25.5%)	
Other or no treatment	19 (5.3%)	15 (4.7%)	68 (11.2%)	
Missing information	32	36	32	
Treatment duration in days (IQR)	216 (120-300)	191 (94-284)	132 (49-235)	<0.0001
Missing	4	2	18	
Response				<0.0001
sCR	3 (0.9%)	5 (1.6%)	5 (0.9%)	
CR	24 (6.9%)	23 (7.6%)	25 (4.6%)	
VGPR	83 (23.7%)	51 (16.8%)	62 (11.4%)	


PR	133 (38.0%)	118 (38.8%)	169 (31.2%)	
SD	73 (20.9%)	55 (18.1%)	99 (18.3%)	
PD	13 (3.7%)	27 (18.1%)	60 (11.1%)	
Deceased	21 (6.0%)	25 (8.2%)	122 (22.5%)	<0.0001**
Missing	43	41	97	0.11**
≥CR	27 (7.7%)	28 (9.2%)	30 (5.5%)	0.16**
≥VGPR	110 (31.4%)	79 (26.0%)	92 (17.0%)	<0.0001**
≥PR	243 (69.4%)	197 (64.8%)	261 (48.2%)	<0.0001**
Follow-up (month)	64.7			

IQR: Interquartile range. sCR: Stringent Complete Remission. CR: Complete Remission. VGPR: Very Good Partial Response. PR: Partial Response. SD: Stable Disease. PD: Progressive Disease. *)Alkylator-based treatment only. Distribution given in N (%) for categorical variables and median (IQR) for continuous unless otherwise stated. P-values calculated using Chi-square test for categorical variables and Kruskal-Wallis test for continuous and ordinal variables unless otherwise stated. **) Chi-square test for trend over the risk groups.



Patients at risk (Patient events)

LR	393	(87)	277	(64)	149	(52)	62	(19)	23	(8)	3
MR	345	(135)	192	(65)	78	(30)	25	(4)	11	(3)	2
HR	639	(408)	209	(92)	79	(32)	23	(8)	9	(3)	3



Patients at risk (Patient events)

LR	361	(194)	134	(67)	37	(16)	14	(2)	2	(0)	0
MR	319	(214)	81	(39)	17	(6)	4	(0)	2	(0)	1
HR	607	(416)	105	(57)	26	(11)	5	(1)	3	(0)	0

This article is protected by copyright. All rights reserved.